Vapaliximab

Drug Profile

Vapaliximab

Alternative Names: BTT-1002; Huvap

Latest Information Update: 02 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioTie Therapies; University of Cambridge; University of Turku
  • Developer BioTie Therapies
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Inflammation; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 24 Apr 2012 Vapaliximab is no longer licensed to Seikagaku Corporation in Japan, Taiwan, Singapore, Australia and New Zealand
  • 19 Jul 2004 This compound is still in active development - BIO 2004 Annual International Convention (BIO-2004)
  • 08 Jul 2003 The licensing agreement between BioTie Therapies and Seikagaku Corporation has taken effect
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top